[go: up one dir, main page]

EP3817743A4 - Anhydrous compositions of mtor inhibitors and methods of use - Google Patents

Anhydrous compositions of mtor inhibitors and methods of use Download PDF

Info

Publication number
EP3817743A4
EP3817743A4 EP19829819.2A EP19829819A EP3817743A4 EP 3817743 A4 EP3817743 A4 EP 3817743A4 EP 19829819 A EP19829819 A EP 19829819A EP 3817743 A4 EP3817743 A4 EP 3817743A4
Authority
EP
European Patent Office
Prior art keywords
methods
mtor inhibitors
anhydrous compositions
anhydrous
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19829819.2A
Other languages
German (de)
French (fr)
Other versions
EP3817743A1 (en
Inventor
Wesley Harton KAUPINEN
Braham Shroot
Simon David Betson
Charles Rodney GREENAWAY EVANS
Marc Barry Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palvella Therapeutics Inc
Original Assignee
Palvella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palvella Therapeutics Inc filed Critical Palvella Therapeutics Inc
Publication of EP3817743A1 publication Critical patent/EP3817743A1/en
Publication of EP3817743A4 publication Critical patent/EP3817743A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19829819.2A 2018-07-02 2019-07-02 Anhydrous compositions of mtor inhibitors and methods of use Withdrawn EP3817743A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862693283P 2018-07-02 2018-07-02
US201862693635P 2018-07-03 2018-07-03
PCT/US2019/040283 WO2020010073A1 (en) 2018-07-02 2019-07-02 ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE

Publications (2)

Publication Number Publication Date
EP3817743A1 EP3817743A1 (en) 2021-05-12
EP3817743A4 true EP3817743A4 (en) 2022-07-06

Family

ID=69054892

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19829819.2A Withdrawn EP3817743A4 (en) 2018-07-02 2019-07-02 Anhydrous compositions of mtor inhibitors and methods of use

Country Status (4)

Country Link
US (4) US11000513B2 (en)
EP (1) EP3817743A4 (en)
JP (1) JP2021530463A (en)
WO (1) WO2020010073A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Anhydrous compositions of mtor inhibitors and methods of use
CN113194752A (en) 2018-06-01 2021-07-30 康奈尔大学 Combination therapy for PI3K related diseases or disorders
JP2021530463A (en) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． Anhydrous composition of mTOR inhibitor and how to use it
WO2021176263A1 (en) * 2020-03-02 2021-09-10 Shanghai Aucta Pharmaceuticals Co., Ltd. Topical formulations containing mtor inhibitors
EP4085898A1 (en) 2021-05-05 2022-11-09 Sodha Pharma Consulting GmbH Topical formulation comprising sirolimus
WO2022271702A1 (en) * 2021-06-21 2022-12-29 Palvella Therapeutics, Inc. Methods and compositions for treating gorlin syndrome
WO2023039470A1 (en) * 2021-09-10 2023-03-16 Palvella Therapeutics, Inc. Anhydrous compositions of egfr inhibitors and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1534339A1 (en) * 2002-08-14 2005-06-01 Novartis AG Topical anhydrous and ethanol-free ascomycin compositions
WO2008015539A2 (en) * 2006-08-03 2008-02-07 Fernando Ahumada Ayala Topical preparation containing sirolimus for treating inflammatory skin deseases
US20120232087A1 (en) * 2009-11-18 2012-09-13 Silvia Buonamici Methods and compositions for treating solid tumors and other malignancies
US20170290849A1 (en) * 2014-09-05 2017-10-12 The Trustees Of Columbia University In The City Of New York AKT and SHH Pathway Inhibitor Combination Therapy for Treating Basal Cell Carcinomas

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
EP0605161A3 (en) 1992-12-29 1994-10-05 American Home Prod Lowering rhematoid factor levels.
JPH06345646A (en) 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd Lotion preparation
DK72593D0 (en) 1993-06-18 1993-06-18 Symbicom Ab RECOMBINANT PROTEIN
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
US5578609A (en) 1994-03-25 1996-11-26 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
GB2308546B (en) 1994-10-26 1999-06-02 Novartis Ag Topical macrolide compositions
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5631282A (en) 1995-06-07 1997-05-20 Merck & Co., Inc. Triterpenes
CA2213989C (en) 1995-12-28 2007-05-29 Yoshitomi Pharmaceutical Industries Ltd. External preparation for topical administration
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
SI1208847T1 (en) 1996-07-30 2007-06-30 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US7985415B2 (en) 1997-09-10 2011-07-26 Rutgers, The State University Of New Jersey Medical devices employing novel polymers
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
CZ287497B6 (en) 1997-12-30 2000-12-13 Galena, A. S. Topic eye preparations containing immunosuppressive substances
US5994081A (en) 1998-04-27 1999-11-30 Incyte Pharamaceuticals, Inc. Human keratins
US6120756A (en) 1998-08-19 2000-09-19 Philip I. Markowitz Topical anionic salicylate for disorders of the skin
CA2343335C (en) 1998-09-11 2014-05-27 Biogen, Inc. Hedgehog and patched antagonists for inhibiting cell and tissue growth and differentiation and uses therefor
US6238683B1 (en) 1998-12-04 2001-05-29 Johnson & Johnson Consumer Companies, Inc. Anhydrous topical skin preparations
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
WO2002050277A2 (en) 2000-12-21 2002-06-27 Curagen Corporation Protein and nucleic acids encoding same
EP1411938B1 (en) 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
EP1441696B1 (en) 2001-11-01 2010-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method and composition for dry eye treatment
AR039209A1 (en) 2002-04-03 2005-02-09 Novartis Ag INDOLILMALEIMIDA DERIVATIVES
AU2003259803B2 (en) 2002-08-12 2007-08-02 The Regents Of The University Of Michigan Diagnosis and treatment of tuberous sclerosis
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AR043504A1 (en) 2003-03-17 2005-08-03 Novartis Ag PHARMACEUTICAL COMPOSITIONS THAT INCLUDE RAPAMYCIN FOR THE TREATMENT OF INFLAMMATORY DISEASES
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP1663249A4 (en) 2003-09-24 2006-12-20 Bioxell Spa 1,3-DIACLYATED,26,27-ALKYL/HALOALKYL VITAMIN D sb 3 /sb COMPOUNDS AND METHODS OF USE THEREOF
DE10347994A1 (en) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Aqueous aerosol preparation
US7806924B2 (en) 2004-02-18 2010-10-05 Cordis Corporation Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis
JP2007523188A (en) 2004-02-23 2007-08-16 スゲン，インコーポレイティド Treatment of abnormal cell proliferation using C-MET inhibitors and M-TOR inhibitors
JP2007528393A (en) 2004-03-11 2007-10-11 カイセラ バイオファーマシューティカルズ， インコーポレイテッド Compositions and methods for preventing and treating skin conditions and hair conditions
US7018309B2 (en) 2004-05-04 2006-03-28 Bridgestone Sports Co., Ltd. Golf ball
US20050250805A1 (en) 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical ointment formulations
US20050249757A1 (en) 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical cream formulations
US20050250804A1 (en) 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical gel formulations
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US20080124400A1 (en) 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
JP5117190B2 (en) 2004-08-27 2013-01-09 コーディス・コーポレイション Amorphous rapamycin without solvent
WO2006029726A1 (en) 2004-09-16 2006-03-23 Bayer Healthcare Ag Dermally applicable formulations for treating skin diseases in animals
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2006041942A2 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
EP1805192B1 (en) 2004-10-25 2012-10-17 Dekk-Tec, Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
EP1655021B1 (en) 2004-11-09 2008-10-29 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
US20060194769A1 (en) 2005-01-25 2006-08-31 University Of Vermont And State Agricultural College Small molecules that reduce fungal growth
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20060258698A1 (en) 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
CA2598460C (en) 2005-02-16 2013-05-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
EP1856097B1 (en) 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
MX2007009949A (en) 2005-02-16 2007-09-26 Schering Corp Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity.
WO2006088836A2 (en) 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
RU2007134260A (en) 2005-02-16 2009-03-27 Шеринг Корпорейшн (US) Pyrazinyl-Substituted Piperazine-Piperidines with Antagonistic Activity Against CXCR3
CA2598459A1 (en) 2005-02-16 2006-08-24 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
MX2007009945A (en) 2005-02-16 2007-09-26 Schering Corp Heterocyclic substituted piperazines with cxcr3 antagonist activity.
EP1868576A2 (en) 2005-03-17 2007-12-26 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
WO2006123226A2 (en) 2005-05-18 2006-11-23 De Villiers, Malan An inhibitor of mtor for inhibiting the formation of scar tissue
US20070031509A1 (en) 2005-08-04 2007-02-08 Sundae Laxman S Breakthrough to cure psoriasis, psoriatic arthritis and treatment of other unrelated skin disorders, and external rectal and genital itching
EP2452691A3 (en) 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention of diabetic and aged skin
JP2009511582A (en) 2005-10-11 2009-03-19 シェーリング コーポレイション Substituted heterocyclic compounds having CXCR3 antagonist activity
WO2007046935A2 (en) 2005-10-14 2007-04-26 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US20070203171A1 (en) 2006-02-28 2007-08-30 Zhao Jonathon Z Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same
KR20090033865A (en) 2006-07-07 2009-04-06 보오슈 앤드 롬 인코포레이팃드 A composition comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye
AU2007323007A1 (en) 2006-08-11 2008-05-29 Panacea Biotec Limited Particles for delivery of active ingredients, process of making and compositions thereof
JP5541593B2 (en) 2006-08-15 2014-07-09 アボット ラボラトリーズ Composition and drug delivery system comprising rapamycin analog and paclitaxel
WO2008022256A2 (en) 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
JP2010505877A (en) 2006-10-05 2010-02-25 ザ・ジョンズ・ホプキンス・ユニバーシティー Water-dispersible oral, parenteral and topical formulations for low water-soluble drugs using smart polymer nanoparticles
PL2077830T3 (en) 2006-10-17 2013-04-30 Lithera Inc Methods, compositions, and formulations for the treatment of thyroid eye disease
US9205080B2 (en) 2006-11-16 2015-12-08 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
EP2033968A1 (en) 2007-03-02 2009-03-11 EPFL Ecole Polytechnique Fédérale de Lausanne Target of rapamycin modulators of and use thereof
LT2481409T (en) 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2008228764B2 (en) 2007-03-22 2014-05-08 Berg Llc Topical formulations having enhanced bioavailability
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
EP2187900B1 (en) 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
WO2009023877A2 (en) 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions
US20090088373A1 (en) 2007-09-28 2009-04-02 Gallo Richard L Use of compositions to enhance innate immune response
WO2009046436A1 (en) 2007-10-04 2009-04-09 Memorial Sloan-Kettering Cancer Center Methods for inhibiting senescence of epithelial cells
ES2667945T3 (en) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20090130029A1 (en) 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
KR20130128018A (en) 2009-04-10 2013-11-25 하이얀 치 Novel anti-aging agents and methods to identify them
EP2308468A1 (en) 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
KR101267813B1 (en) 2009-12-30 2013-06-04 주식회사 삼양바이오팜 An injectable composition comprising polymeric nanoparticles containing rapamycin with an improved water solubility and a method for preparing the same, and an anticancer composition comprising the same for a combination therapy with radiation
US9629888B2 (en) 2010-03-05 2017-04-25 Leafpro, Llc Composition of matter for delivering lipid-soluble materials, and a method for producing it
PL2571532T3 (en) 2010-05-14 2017-10-31 Abbvie Inc Il-1 binding proteins
US20120022095A1 (en) 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
IT1400977B1 (en) 2010-07-01 2013-07-05 Euticals Spa NEW COMPLEXES OF PHARMACEUTICAL, SOLID, SOLUBLE IN WATER AND THEIR WATER SOLUTIONS FOR ORAL, OPHTHALMIC, TOPICAL OR PARENTERAL USE, CONTAINING A MACROLIDE AND SOME CYCLODEXTRINES.
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
JP2014500275A (en) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド Methods for treating baldness and for promoting hair growth
AU2012211809A1 (en) 2011-01-31 2013-09-05 Osaka University Externally-used drug for treating skin disorder and method for producing same
WO2012142145A1 (en) 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
PT2714010T (en) 2011-05-25 2017-05-05 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
EP2714008B1 (en) 2011-05-25 2016-12-14 Novaliq GmbH Pharmaceutical composition for administration to nails
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
US20130323284A1 (en) * 2012-06-05 2013-12-05 Jazzya Investments USE OF mTOR INHIBITORS TO TREAT BACTERIAL INFECTION
US20150202187A1 (en) 2012-06-26 2015-07-23 Sarah Bacus Compositions and methods for treatment of vitiligo
EP2895172B1 (en) 2012-09-12 2019-02-06 Rigel Pharmaceuticals, Inc. Treatment for vitiligo
CA2883003C (en) 2012-09-12 2021-11-16 Novaliq Gmbh Semifluorinated alkane compositions
US20150051242A1 (en) 2012-10-26 2015-02-19 Zhejiang Zylox Medical Device Co., Ltd. Rafamycin analogs and methods for making same
US20150328193A1 (en) 2012-12-17 2015-11-19 The Brigham And Women's Hospital, Inc. Treatment of mtor hyperactive related diseases and disorders
CA2899206C (en) 2013-01-24 2019-07-09 Transderm, Inc. Compositions for transdermal delivery of mtor inhibitors
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
MY177476A (en) 2013-02-22 2020-09-16 Pfizer Pyrrolo [2,3-d]pyrimidine derivatives as inhibitors of janus kinases (jak)
WO2014132227A1 (en) 2013-02-27 2014-09-04 Batt Laurie Robert Transdermal formulations
US20140271671A1 (en) 2013-03-14 2014-09-18 Eli Lilly And Company Random homozygous gene perturbation (rhgp) with thermal assymetric interlaced (tail)-pcr
DE102013104441A1 (en) 2013-04-30 2014-10-16 Bodo C. Melnik Acne drug and process for its preparation
US9717722B2 (en) 2013-05-13 2017-08-01 New York University Methods and agents for treating tyrosinase-positive albinism
EP3052504B1 (en) 2013-10-04 2019-02-06 Universität Basel Conformationally restricted pi3k and mtor inhibitors
JP6529012B2 (en) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド Rapamycin for the treatment of lymphangiyomyomatosis
US20150265582A1 (en) 2014-02-11 2015-09-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HUP1400075A2 (en) * 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical composition containing them
WO2015154084A1 (en) 2014-04-04 2015-10-08 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
SG11201607950SA (en) 2014-05-27 2016-10-28 Almirall Sa Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile
GB201419540D0 (en) 2014-11-03 2014-12-17 Nanomerics Ltd Delivery of drugs
US20160184279A1 (en) 2014-12-10 2016-06-30 Transderm, Inc. METHODS OF TREATING PAIN AND/OR ITCH WITH SMALL MOLECULE INHIBITORS TARGETING AN mTOR PATHWAY
CN115192517A (en) 2015-02-02 2022-10-18 参天制药股份有限公司 Multifoam and eyelid application thereof
EP3292123B1 (en) 2015-05-06 2020-07-22 Plexxikon Inc. Solid forms of a compound modulating kinases
KR20180081501A (en) 2015-09-24 2018-07-16 드렉셀유니버시티 Novel compositions and methods for treating or preventing dermatological disorders
US10682340B2 (en) * 2016-06-30 2020-06-16 Durect Corporation Depot formulations
CA3032473A1 (en) 2016-08-10 2018-02-15 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Anhydrous compositions of mtor inhibitors and methods of use
US10456383B2 (en) 2017-06-01 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted approach in the management of Epidermolysis bullosa
JP2021530463A (en) * 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． Anhydrous composition of mTOR inhibitor and how to use it
WO2022271702A1 (en) 2021-06-21 2022-12-29 Palvella Therapeutics, Inc. Methods and compositions for treating gorlin syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1534339A1 (en) * 2002-08-14 2005-06-01 Novartis AG Topical anhydrous and ethanol-free ascomycin compositions
WO2008015539A2 (en) * 2006-08-03 2008-02-07 Fernando Ahumada Ayala Topical preparation containing sirolimus for treating inflammatory skin deseases
US20120232087A1 (en) * 2009-11-18 2012-09-13 Silvia Buonamici Methods and compositions for treating solid tumors and other malignancies
US20170290849A1 (en) * 2014-09-05 2017-10-12 The Trustees Of Columbia University In The City Of New York AKT and SHH Pathway Inhibitor Combination Therapy for Treating Basal Cell Carcinomas

Also Published As

Publication number Publication date
US11679101B2 (en) 2023-06-20
US20230263781A1 (en) 2023-08-24
JP2021530463A (en) 2021-11-11
US20200000778A1 (en) 2020-01-02
EP3817743A1 (en) 2021-05-12
US20240398766A1 (en) 2024-12-05
US11000513B2 (en) 2021-05-11
WO2020010073A1 (en) 2020-01-09
US20210244713A1 (en) 2021-08-12
US12329748B2 (en) 2025-06-17

Similar Documents

Publication Publication Date Title
IL267869A (en) Anhydrous compositions of mtor inhibitors and methods of use
EP3817743A4 (en) Anhydrous compositions of mtor inhibitors and methods of use
EP3962479A4 (en) Kcnt1 inhibitors and methods of use
EP3810617A4 (en) Ectonucleotidase inhibitors and methods of use thereof
IL287768A (en) Kcnt1 inhibitors and methods of use
EP3969439A4 (en) Acss2 inhibitors and methods of use thereof
EP3291809A4 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP3986894A4 (en) Ectonucleotidase inhibitors and methods of use thereof
EP3829307A4 (en) Bismuth-thiol compositions and methods of use
EP3959197A4 (en) Papd5 inhibitors and methods of use thereof
EP3291810A4 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP3801525A4 (en) Inhibitors of prolyl-trna-synthetase
HK40052058A (en) Anhydrous compositions of mtor inhibitors and methods of use
HK40118863A (en) Masp-2 inhibitors and methods of use
HK40107376A (en) Masp-2 inhibitors and methods of use
HK40104802A (en) Masp-2 inhibitors and methods of use
HK40104799A (en) Masp-2 inhibitors and methods of use
HK40064703A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40062239A (en) Acss2 inhibitors and methods of use thereof
HK40063536A (en) Acss2 inhibitors and methods of use thereof
HK40069053A (en) Kcnt1 inhibitors and methods of use
HK40049706A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40064811A (en) Caspase inhibitors and methods of use thereof
HK40065278A (en) Nanotransposon compositions and methods of use
HK40081116A (en) Allosteric egfr inhibitors and methods of use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052058

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220608

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/18 20170101ALI20220601BHEP

Ipc: A61K 47/14 20170101ALI20220601BHEP

Ipc: A61K 47/10 20170101ALI20220601BHEP

Ipc: A61K 31/5377 20060101ALI20220601BHEP

Ipc: A61P 35/00 20060101ALI20220601BHEP

Ipc: A61K 47/38 20060101ALI20220601BHEP

Ipc: A61K 47/34 20170101ALI20220601BHEP

Ipc: A61K 47/32 20060101ALI20220601BHEP

Ipc: A61K 47/44 20170101ALI20220601BHEP

Ipc: A61K 47/24 20060101ALI20220601BHEP

Ipc: A61K 47/22 20060101ALI20220601BHEP

Ipc: A61K 47/26 20060101ALI20220601BHEP

Ipc: C07D 491/00 20060101ALI20220601BHEP

Ipc: A61K 9/00 20060101ALI20220601BHEP

Ipc: A61K 31/436 20060101AFI20220601BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230612

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231024